Los Angeles Institute for Metabolic Research

04/28/2026

¿Sabías que la enfermedad del hígado graso no alcohólico ocurre cuando se acumula grasa en el hígado en personas que consumen poco o nada de alcohol? Está relacionada con condiciones como obesidad, resistencia a la insulina, prediabetes y diabetes tipo 2.

La mayoría de las personas no presentan síntomas, por lo que puede pasar desapercibida. Sin embargo, con el tiempo puede avanzar a inflamación, fibrosis (cicatrización del hígado) y enfermedades hepáticas más graves.

¿La buena noticia? Detectarlo a tiempo hace la diferencia.

En nuestro instituto, ofrecemos el FibroScan, un ultrasonido rápido, y no invasivo que mide la grasa y rigidez del hígado para evaluar su salud.

¡Toma el control de tu salud hoy!
Agenda tu cita aquí: https://metabolic.la/schedule-an-appointment

04/10/2026

Dr. Frías is attending the Obesity Medicine 2026 Conference in San Diego!

This conference brings together top doctors and researchers to share the latest advancements in obesity care—from new medications and nutrition strategies to mental health support and innovative technology.

Did you know❓
In Los Angeles County, 1 in 4 adults have obesity, and more than half are either overweight or obese.

That’s why our work at Los Angeles Institute for Metabolic Research matters. We are committed to bringing innovative clinical research opportunities to our local community, helping patients access cutting-edge treatments while contributing to the future of healthcare.

Want to learn more about the work we’re doing at Los Angeles Institute for Metabolic Research? Explore our work: https://metabolic.la/

03/23/2026

🚶‍♀️💙 We were proud to be part of the Breakthrough T1D Walk this past Saturday at the Rose Bowl in Pasadena!

It was amazing connecting with organization members, everyone who stopped by our booth, and most importantly, the incredible T1D community. Your stories, strength, and support for one another are truly inspiring.

Breakthrough T1D continues to play a critical role in advancing research, advocacy, and progress toward better treatments—and ultimately a cure. We’re honored to support that mission.

At our booth, we shared information about ongoing clinical research at our Institute, including a study evaluating a once-weekly, long-acting insulin for individuals with T1D.

Thank you to everyone who stopped by to speak with us!

If you or someone you know may be interested in participating in clinical research, we welcome you to connect with our team.

We look forward to continuing this work together and we’re already looking forward to next year! 🙌 ✨

03/23/2026

Clinical research can serve as a compass, guiding the future of type 2 diabetes (T2D) treatment. A local study is enrolling adults with T2D and elevated cortisol. Those who qualify will receive:

✅ Study-related medical care at no cost
✅ Regular check-ins with research teams and medical staff
✅ Possible reimbursement for travel + expenses

Learn more: https://metabolic.la/captain-t2d-study-2026.

03/19/2026

Steering the journey with type 2 diabetes (T2D) can feel like facing unpredictable tides. A local research study is investigating a medication for adults managing T2D. Those who qualify will receive:

✅ Study-related medical care at no cost
✅ Regular check-ins with research teams and medical staff
✅ Possible reimbursement for travel + expenses

Learn more: https://metabolic.la/captain-t2d-study-2026.

03/16/2026

Dr. Juan Pablo Frías, Medical Director and Principal Investigator at the Los Angeles Institute for Metabolic Research, presented 52-week data of icovamenib in people with type 2 diabetes at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Barcelona, Spain.

Dr. Frías was an invited speaker at the 1st ATTD Congress in Prague in 2008, where he presented on two therapies that were just emerging at the time—the first GLP-1 receptor agonist (exenatide twice daily) and the first amylin analog (pramlintide) for the treatment of diabetes.

From those early GLP-1 and amylin therapies to today’s next generation of metabolic treatments, the field has advanced tremendously.

Over the past two decades, investigators and staff now at the Los Angeles Institute for Metabolic Research have contributed to the clinical development of many important therapies for diabetes, obesity, and metabolic liver disease—and we remain committed to continuing to help advance the field.

03/11/2026

The people behind the purpose.

Every day, our team shows up with a shared commitment: to improve the lives of people affected by diabetes, obesity, metabolic liver disease, and related conditions. Through high-quality, community-connected clinical research, we’re working to advance safe and effective therapies that make a real difference.

🔗 Learn more at https://metabolic.la/.

03/02/2026

Juan Pablo Frías, MD, Medical Director and Principal Investigator at the Los Angeles Institute for Metabolic Research, with his brother, Patrick Frías, MD, Co-President and CEO of Rady Children’s Health, at the 117th Anniversary Kaleidoscope Charity Ball benefiting the Peckham Center for Cancer and Blood Disorders at Rady Children’s Hospital San Diego.

A meaningful evening at the iconic Hotel del Coronado in support of extraordinary pediatric care and research.

03/02/2026

The state-of-the-art FibroScan® system is now part of everyday care at the Los Angeles Institute for Metabolic Research — and it’s already playing an important role in our latest clinical research efforts.

This non-invasive technology is being used to support screening and enrollment for our MASLD clinical trial, helping assess liver health and identify eligible participants. It also remains a key tool across our metabolic liver disease research, from community screenings to active studies.

We’re proud to combine advanced technology with innovative research to improve liver health and expand treatment options for our community.

02/24/2026

In case you missed it — Dr. Juan Pablo Frías recently spoke on “The Central Role of Weight Management in the Care of People with Type 2 Diabetes.”

In this webinar, he discusses how obesity drives type 2 diabetes and related complications, why early weight management should be a primary treatment goal, and how emerging GLP-1 and multi-agonist therapies are transforming care across glycemic control, cardiovascular risk, and metabolic liver disease.

▶️ Watch the full webinar to learn more: https://www.youtube.com/watch?v=Gr2kOE-ve28.

Join us in this webinar titled, “The Central Role of Weight Management in the Care of People with Type 2 Diabetes,” by Dr. Juan Frias where he shared how obe...